Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model-Reference-Cited by-同舟云学术

Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model

Published:2022-12-06 Issue:1 Volume:15 Page:
ISSN:1756-0500
Container-title:BMC Research Notes
language:en
Short-container-title:BMC Res Notes

Author:

Putri Septiara^ORCID,Nugraha Ryan R.,Pujiyanti Eka,Thabrany Hasbullah,Hasnur Hanifah,Istanti Novita D.,Evasari Diah,Afiatin

Abstract

Abstract Objective Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are main modalities for end stage renal disease (ESRD) patients, and those have been covered by National Health Insurance (NHI) scheme since 2014 in Indonesia. This study aims to update the cost-effectiveness model of CAPD versus HD in Indonesia setting. Results Compared to HD, CAPD provides good value for money among ESRD patients in Indonesia. Using societal perspective, the total costs were IDR 1,348,612,118 (USD 95,504) and IDR 1,368,447,750 (USD 96,908), for CAPD and HD, respectively. The QALY was slightly different between two modalities, 4.79 for CAPD versus 4.22 for HD. The incremental cost-effectiveness ratio (ICER) yields savings of IDR 34,723,527/QALY (USD 2460).

Funder

Baxter Indonesia

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://link.springer.com/content/pdf/10.1186/s13104-022-06252-4.pdf

Reference25 articles.

1. Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021;52:98–107.

2. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–33.

3. Wang V, Vilme H, Maciejewski ML, Boulware LE. The economic burden of chronic kidney disease and end-stage renal disease. Semin Nephrol. 2016;36:319–30.

4. Coresh J. Update on the burden of CKD. J Am Soc Nephrol. 2017;28:1020–2.

5. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–82.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutting back on low-value health care practices supports sustainable kidney care;Kidney International;2024-06

2. Peritoneal dialysis vs. hemodialysis among patients with end-stage renal disease in Iran: which is more cost-effective?;BMC Nephrology;2024-03-06

3. Evolution of Health Technology Assessment in Indonesia: Supply Landscape, Implementation, and Future Directions;Health Systems & Reform;2023-12-31